185 related articles for article (PubMed ID: 30701428)
1. Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.
Mudunuru J; Ren C; Taft DR; Maniar M
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):531-538. PubMed ID: 30701428
[TBL] [Abstract][Full Text] [Related]
2. Gender-related pharmacokinetics and absolute bioavailability of diosbulbin B in rats determined by ultra-performance liquid chromatography-tandem mass spectrometry.
Yang B; Wang X; Liu W; Zhang Q; Chen K; Ma Y; Wang C; Wang Z
J Ethnopharmacol; 2013 Oct; 149(3):810-5. PubMed ID: 23954278
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
5. Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent.
Green CE; Swezey R; Bakke J; Shinn W; Furimsky A; Bejugam N; Shankar GN; Jong L; Kapetanovic IM
Cancer Chemother Pharmacol; 2011 May; 67(5):995-1006. PubMed ID: 20623225
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats.
Xie B; Jiang SQ; Shen XL; Wu HQ; Hu YJ
J Ethnopharmacol; 2021 Dec; 281():114544. PubMed ID: 34419608
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Jia L; Coward LC; Kerstner-Wood CD; Cork RL; Gorman GS; Noker PE; Kitada S; Pellecchia M; Reed JC
Cancer Chemother Pharmacol; 2008 Jan; 61(1):63-73. PubMed ID: 17356822
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro metabolism and pharmacokinetics of cholinesterase inhibitor deoxyvasicine from aerial parts of Peganum harmala Linn in rats via UPLC-ESI-QTOF-MS and UPLC-ESI-MS/MS.
Deng G; Liu W; Ma C; Rong X; Zhang Y; Wang Y; Wu C; Cao N; Ding W; Guan H; Cheng X; Wang C
J Ethnopharmacol; 2019 May; 236():288-301. PubMed ID: 30872168
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
10. Gender differences pharmacokinetics, bioavailability, hepatic metabolism and metabolism studies of Pinnatifolone A, a sesquiterpenoid compound, in rats by LC-MS/MS and UHPLC-Q-TOF-MS/MS.
Peng W; Li Z; Cai D; Yi X; Yue Jeff Zhang J; Zhong G; Ouyang H; Feng Y; Yang S
Phytomedicine; 2023 Jan; 109():154544. PubMed ID: 36610155
[TBL] [Abstract][Full Text] [Related]
11. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of Ebracteolatain A, a potential anti-cancer compound, as determined by an optimized ultra-performance liquid chromatography tandem mass spectrometry method.
Lv L; Liu Y; Li L; Qin FL; Li CJ; Zhou YQ; Zhou YN; Wang H; Jiao Y; Zhao L
J Pharm Biomed Anal; 2019 May; 169():279-287. PubMed ID: 30884326
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ginkgo Leaf Tablets on the Pharmacokinetics of Amlodipine in Rats.
Wang R; Zhang H; Sun S; Wang Y; Chai Y; Yuan Y
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):825-833. PubMed ID: 26650374
[TBL] [Abstract][Full Text] [Related]
16. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound.
S S; Vuppu S
J Pharm Biomed Anal; 2020 Feb; 179():113000. PubMed ID: 31787460
[TBL] [Abstract][Full Text] [Related]
17. Analysis of trans-2,6-difluoro-4'-(N,N-dimethylamino)stilbene (DFS) in biological samples by liquid chromatography-tandem mass spectrometry: metabolite identification and pharmacokinetics.
Yeo SC; Sviripa VM; Huang M; Kril L; Watt DS; Liu C; Lin HS
Anal Bioanal Chem; 2015 Sep; 407(24):7319-32. PubMed ID: 26229026
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings.
Riyazuddin M; Valicherla GR; Husain A; Hussain MK; Shukla M; Katekar R; Gupta AP; Singh P; Banerjee D; Hajela K; Gayen JR
J Pharm Biomed Anal; 2019 Jan; 162():205-214. PubMed ID: 30265980
[TBL] [Abstract][Full Text] [Related]
19. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat.
Zuo Z; Tam YK; Diakur J; Wiebe LI
J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist.
Vachharajani NN; Yeleswaram K; Boulton DW
J Pharm Sci; 2003 Apr; 92(4):760-72. PubMed ID: 12661062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
